SHANGHAI, Aug. 11, 2026 /PRNewswire/ -- Laekna (2105.HK) announced today that the New Drug Application (NDA) for LAE002 (afuresertib) has been accepted by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for the treatment of patients with...
Hence then, the article about new drug application for lae002 afuresertib accepted by china s national medical products administration was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( New Drug Application for LAE002 (afuresertib) Accepted by China's National Medical Products Administration )
Also on site :
- Investors thought they were buying pre-IPO OpenAI and SpaceX shares. Their cash went to strip clubs, Bloomingdale’s, and shopping on Amazon, SEC alleges
- In 1983, Congress set aside $42 million to move a Pennsylvania town off a burning coal seam; Centralia went from 1,017 residents to five by 2020
- Pandora’s MLC Royalties Lawsuit Heads to Trial as Judge Declines to Sift Through ‘Corpulent’ Case File